Drugs that target “epigenetic” changes may help treat or slow the progression of lung cancer.
A protein involved in repairing DNA damage associated with gastric reflux may play a tumor suppressor role in the esophagus and could represent a target for therapies to combat esophageal cancer.
Even when lung operations for suspected cancer resection results in a benign diagnosis, there still may be significant benefits to the procedure, new research suggests.
Molecular players involved in colon cancer progression could provide new biomarkers to indicate invasiveness and prognosis.
A. Scott Pearson, associate professor of surgery at Vanderbilt University Medical Center, will appear on “A Word on Words with John Seigenthaler” this Sunday, July 17, at 10:30 a.m.